Spur provides update on FLT201
Syncona Limited
Spur provides update on FLT201 and planned Phase III clinical trial
8 July 2024
Syncona Ltd, a leading life science investor focused on creating, building and scaling global leaders in life science, notes that its portfolio company Spur Therapeutics ("Spur") has completed enrolment in the Phase I/II GALILEO-1 clinical trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease. Based on the encouraging data from this Phase I/II trial, Spur has selected a single infusion of FLT201 at a low dose of 4.5e11 vg/kg for its Phase III trial expected to start in CY2025.
Six patients have been dosed in the GALILEO-1 trial and were treated with a single infusion of FLT201 at a dose of 4.5e11 vg/kg. Two of the six patients have completed the full nine months of follow-up. The others have been followed for between 16 and 38 weeks after dosing. One patient was identified to have pre-existing neutralising antibodies to the AAV3 capsid used to deliver FLT201, below the protocol cut-off. This patient has been excluded from the efficacy analysis. All six patients are included in the safety analysis, with FLT201 continuing to demonstrate a favourable safety and tolerability profile.
Efficacy data as of 30 June 2024 data cut-off:
· Lyso-Gb1, an established biomarker of clinical response in Gaucher disease, was substantially reduced in the four patients with persistently high lyso-Gb1 levels, despite years of treatment with currently approved therapies.
o One patient entered the trial with well-controlled lyso-Gb1, and these levels have been maintained.
· Maintenance of normal levels, or improvement to normal levels, of haemoglobin and platelets seen in five patients, which are well-accepted regulatory endpoints for Gaucher disease.
· Improvement seen in bone marrow burden in five patients, which shows FLT201 is reaching deeper tissues that are poorly addressed by currently approved therapies.
· Clinically relevant improvement in patient-reported pain and fatigue, leading to improved function, in the one patient who entered the trial with debilitating chronic pain and fatigue.
· Two patients developed antibodies to GCase, the enzyme that is deficient in people with Gaucher disease, but still experienced benefits from treatment with FLT201.
o Improvements seen in lyso-Gb1 and bone marrow burden from baseline, as well as maintenance of haemoglobin and platelets in normal ranges.
o In the patient with longest exposure (greater than three months beyond detection of antibodies), the antibodies appear to have been transient and improvements in clinical parameters continue to be observed.
Spur expects to report additional data from the Phase I/II GALILEO-1 trial in the second half of 2024.
Chris Hollowood, CEO of Syncona Investment Management Limited and Chair of Spur, said: "We continue to be highly encouraged by the data coming from the FLT201 programme in Gaucher disease. The safety and tolerability of the treatment, alongside these compelling efficacy signals, suggest FLT201 has the potential to play an important role in the treatment of patients with Gaucher disease. Spur is expecting to report further data on FLT201 in the second half of the year, and we look forward to working with the team as they move towards initiating a Phase III trial in CY2025."
Spur's announcement is copied below and can be accessed on the company's website at https://spurtherapeutics.com/.
[ENDS]
Enquiries
Syncona Ltd
Natalie Garland-Collins / Fergus Witt
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.
We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.
Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial
Single infusion of FLT201 at low dose of 4.5e11 vg/kg demonstrates compelling safety and benefit
Expect to initiate Phase 3 registrational trial in 2025
LONDON, July 8, 2024 - Spur Therapeutics, formerly Freeline Therapeutics, today announced it has completed enrollment in the Phase 1/2 GALILEO-1 clinical trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease. Based on compelling safety and efficacy data from the GALILEO-1 trial, Spur has selected a single infusion of FLT201 at a low dose of 4.5e11 vg/kg for further development in a Phase 3 trial expected to begin next year.
"We are very pleased with the progress of FLT201," said Michael Parini, Chief Executive Officer of Spur Therapeutics. "The data from the GALILEO-1 trial strengthen our conviction in FLT201's potential to set a new standard of care for Gaucher disease and give us confidence to move forward at the current dose, which has shown strong signals of efficacy combined with a favorable safety and tolerability profile. We are preparing to start the Phase 3 trial next year and are committed to bringing forward what we believe is a first- and best-in-class gene therapy to redefine the treatment landscape for Gaucher disease."
Six patients have been dosed in GALILEO-1, a first-in-human, international, multicenter dose-finding study in adults with Gaucher disease Type 1. All patients were treated with a single infusion of FLT201 at a dose of 4.5e11 vg/kg. Two of the six patients have completed the full nine months of follow-up. The others have been followed for between 16 and 38 weeks after dosing. All six patients are included in the safety analysis. Five of the six patients are included in the efficacy analysis; one patient with detectable pre-existing neutralizing antibodies (NAbs) to the AAVS3 capsid below the protocol cut-off has been excluded from the efficacy analysis.
Data as of the June 30, 2024 data cut-off demonstrate:
· Favorable safety and tolerability.
· Dramatic reductions in glucosylsphingosine (lyso-Gb1) - a Gaucher-specific biomarker that is one of the best predictors of disease severity and clinical response - in patients with persistently high levels despite years of treatment with currently approved therapies (4/4).
· Maintenance of lyso-Gb1 levels in a patient who entered the trial with well-controlled lyso-Gb1 (1/1).
· Maintenance of normal levels or improvement to normal levels of hemoglobin and platelets, which are well-accepted regulatory endpoints for Gaucher disease (5/5).
· Improvement in bone marrow burden (5/5), which shows FLT201 is reaching deeper tissues that currently approved therapies poorly address.
· Clinically relevant improvement in patient-reported pain and fatigue, leading to improved function, in the one patient who entered trial with debilitating chronic pain and fatigue.
· Patients experienced these benefits regardless of antibodies to glucocerebrosidase (GCase) (n=2), the enzyme that is deficient in people with Gaucher disease, consistent with clinical experience with enzyme replacement therapy and preclinical data for FLT201.
o Improvements in lyso-Gb1 and bone marrow burden from baseline, as well as maintenance of hemoglobin and platelets in normal ranges, continue to be observed after antibodies were detected.
o In the patient with longest exposure (greater than three months beyond detection of antibodies), the antibodies appear to have been transient and improvements in clinical parameters continue to be observed.
Spur expects to report additional data from the GALILEO-1 trial in the second half of 2024.
FLT201 has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration, Priority Medicines (PRIME) designation by the European Medicines Agency and the Innovative Licensing and Access Pathway (ILAP) by the U.K. Medicines and Healthcare products Regulatory Agency. Designed to expedite the drug development process for investigational therapies intended to treat, modify, reverse or cure a serious or life-threatening disease, the designations provide opportunities for enhanced interactions with regulators and expedited review processes. Spur is actively engaging with regulators as it prepares for the planned Phase 3 trial of FLT201.
About FLT201
FLT201 is an adeno-associated virus (AAV) gene therapy candidate that is currently being investigated in the Phase 1/2 GALILEO-1 clinical trial in adults with Gaucher disease. FLT201 leverages Spur's proprietary and potent AAVS3 capsid to deliver GCase85, a rationally engineered longer-acting version of the enzyme deficient in people with Gaucher disease, with the goal of stopping disease progression, reducing or eliminating symptoms, and allowing patients to come off current lifelong treatments. Preclinical and clinical data for FLT201 have shown robust and durable expression and a substantial reduction in the toxic buildup of substrate that results from the enzyme deficiency. For more information about the GALILEO-1 trial, please visit clinicaltrials.gov (NCT05324943).
About Gaucher Disease
Gaucher disease is caused by a mutation in the GBA1 gene that results in abnormally low levels of glucocerebrosidase (GCase), an enzyme needed to metabolize a certain type of lipid. As a result, harmful substrates glucosylceramide (Gb-1) and glucosylsphingosine (lyso-Gb1) build up in cells, which then accumulate in tissues and organs throughout the body, causing inflammation and dysfunction. Despite treatment with currently approved therapies, many people with Gaucher disease continue to experience debilitating symptoms, including enlarged organs, fatigue, bone pain and reduced lung function. Gaucher disease affects approximately 18,000 people in the United States, United Kingdom, France, Germany, Spain, Italy and Israel.
About Spur Therapeutics
Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions. By optimizing every component of its product candidates, Spur aims to unlock the true potential of gene therapy to realize outsized clinical results. Spur is advancing a breakthrough gene therapy candidate for Gaucher disease and a potential first-in-class gene therapy candidate for adrenomyeloneuropathy, as well as a research strategy to move gene therapy into more prevalent diseases, including forms of Parkinson's, dementia, and cardiovascular disease. Expanding our impact, and advancing the practice of genetic medicine.
Toward life-changing therapies, and brighter futures. Toward More™
For more information, visit www.spurtherapeutics.com or connect with Spur on LinkedIn and X.
Contact
Naomi Aoki
naomi.aoki@spurtherapeutics.com
+ 1 617 283 4298
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 9 hours ago Savannah Energy
- 10 hours ago Buccaneer Energy PLC
- 10 hours ago Savannah Energy
- 11 hours ago Carclo
- 11 hours ago Schroder Japan Growth Fund